

Injectable Drug Delivery Market Report 2017– Global Analysis and Forecast to 2024

Injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.

DALLAS, TEXAS, UNITED STATES, June 16, 2017 /EINPresswire.com/ -- Injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024

“


The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024”

Data Bridge Market Research

South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Global Injectable Drug Delivery Market 2017-2024

Global Injectable Drug Delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a **CAGR of 11.5%** in the forecast period 2017 to 2024.



 **DATA BRIDGE**
MARKET RESEARCH

Ask for Sample of the report: <http://databridgemarketresearch.com/request-a-sample/?chalet=Global%20Injectable%20Drug%20Delivery%20Market>

Segmentation:

By Type:

1. Devices

- Conventional Injection
- Self-Injection

2. Formulations

- Conventional Drug Delivery,
- Noble Drug Delivery,
- Long Acting Injection Formulations

By Applications:

- Autoimmune Diseases
- Hormonal Disorders
- Orphan Diseases
- Oncology

By Usage Pattern:

- Curative Care
- Immunizations

By Mode of Administration:

- Skin
- Circulatory
- Organs
- Central Nervous System

By End User:



- Hospitals & Clinics
- Home Care Settings
- Research Laboratories
- Pharma & Biotech Companies

By Geography:

- North America
- Europe
- Asia-Pacific
- South America
- Middle East Africa

Some of the major factors driving the market for injectable drug delivery market are increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).

North America is expected to dominate the market for Injectable Drug Delivery in 2016 and APAC is expected to be growing with highest CAGR in the forecast period 2017- 2024.



Read More on the market trends of

Global Injectable Drug Delivery Market: <http://databridgemarketresearch.com/global-injectable-drug-delivery-market-is-growing-at-a-significant-rate-in-the-forecast-period-2017-2024/>

The major players in the injectable drug delivery are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz,

Terumo Corporation, Teva Pharmaceuticals Industries Ltd., Bepak, Antares Pharma, Elcam Medical, Haselmeier, Mylan N.V., Novo Nordisk, Owen Mumford Ltd, Sanofi, West Pharmaceutical Services, Inc, Ypsomed Holding AG.

Some Recent Developments:

- Becton, Dickinson and Company

1. In August 2016, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it has received U.S. Food and Drug Administration (FDA) clearance for its new syringe for patients using Humulin R U-500 insulin vials.

- Pfizer

1. In March 2017, Pfizer Inc. and Merck announced the FDA approval of BAVENCIO (avelumab) Injection, for intravenous use which is used for the treatment of adults and pediatric patients and with metastatic Merkel cell carcinoma (mMCC)

Purchase Request: <http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/>

Table Of Contents:

1. INTRODUCTION

1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET

1.2. MARKET SEGMENTATION & COVERAGE

2. RESEARCH METHODOLOGY

2.1. KEY TAKEAWAYS

2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE

2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

4.1. OVERVIEW

4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS

4.3. MARKET OVERVIEW

4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE

5.1. OVERVIEW

5.2. INJECTABLE [DRUG DELIVERY DEVICES](#)

5.3. INJECTABLE DRUG DELIVERY FORMULATIONS

6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

6.1. OVERVIEW

6.2. CONVENTIONAL INJECTION DEVICES

6.3. SELF INJECTION DEVICES

6.3.1. NEEDLE FREE INJECTOR

7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE

7.1. OVERVIEW

7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3. NOVEL DRUG DELIVERY FORMULATIONS

8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS

8.1. OVERVIEW

8.2. AUTOIMMUNE DISEASES

8.3. HORMONAL DISORDER

- 8.4. ORPHAN DISEASES
- 8.5. ONCOLOGY
- 8.6. OTHERS
- 9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
 - 9.1. OVERVIEW
 - 9.2. CURATIVE CARE
 - 9.3. IMMUNIZATIONS
 - 9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
- 10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
 - 10.1. OVERVIEW
 - 10.2. SKIN
 - 10.3. CIRCULATORY/MUSKOSKELETAL
 - 10.4. ORGANS
 - 10.5. CENTRAL NERVOUS SYSTEM
- 11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
 - 11.1. OVERVIEW
 - 11.2. HOSPITALS AND CLINICS
 - 11.3. HOME HEALTHCARE SETTINGS
 - 11.4. RESEARCH LABORATORIES
 - 11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
 - 11.6. OTHER END USERS
- 12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
 - 12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
 - 12.1.2. EUROPE
 - 12.1.3. ASIA-PACIFIC (APAC)
 - 12.1.4. LATIN AMERICA
 - 12.1.5. MIDDLE EAST AND AFRICA
 - 12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
- 13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
 - 13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
 - 13.7. MERGERS & ACQUISITIONS
 - 13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
 - 13.9. EXPANSIONS
 - 13.10. REGULATORY CHANGES
 - 13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
- 14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
 - 14.1. BAXTER INTERNATIONAL, INC.
 - 14.2. BECTON, DICKINSON AND COMPANY
 - 14.3. GERRESHEIMER, AG
 - 14.4. PFIZER, INC
 - 14.5. SCHOTT AG
 - 14.6. ALKERMES PLC
 - 14.7. ELI LILLY AND COMPANY

- 14.8. SANDOZ
- 14.9. TERUMO CORPORATION
- 14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD
- 15. APPENDIX
 - 15.1. RELATED REPORTS
 - 15.2. CUSTOMIZABLE OPTIONS
 - 15.3. SOURCE SHEET
 - 15.4. BIBLIOGRAPHY
- 16. ABOUT DATA BRIDGE MARKET RESEARCH

Vishal Dwivedi
Data Bridge Market Research Private Ltd.
+1-888-387-2818
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.